Pelcitoclax

Phase 1Small molecule

Pelcitoclax is one of 95 small molecule programs targeting T-cell acute lymphoblastic leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

T-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Endometrial CancerActive, not recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Endometrial CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

258 competitors in Endometrial Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

55 2

Keytruda

Merck & Co.

Phase 3

20 3

Femara

Novartis

Phase 3

19 4

Paraplatin

AAvyxa

Phase 3

38 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

26 6

Adriamycin

Pfizer

Phase 3

8 7

Lynparza

AstraZeneca

Phase 3

7 8

Lenvima

Eisai

Phase 3

6 9

Tecentriq

Roche

Phase 3

4 10

Trodelvy

Gilead

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Endometrial Cancer

NCT05691504

Q2 2032

Phase 1Not yet recruiting

T-Cell Acute Lymphoblastic Leukemia

NCT07428486

Clinical

Trials by Indication[1]

T-cell acute lymphoblastic leukemia1 trial

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07428486·24 enrolled

Neuroendocrine Tumors1 trial

A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

Terminated· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1·NCT04893759·2 enrolled

Endometrial Cancer1 trial

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05691504·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Pelcitoclax. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pelcitoclax compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pelcitoclax. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ascentage Pharma Group Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Ascentage Pharma Group Inc.

Pelcitoclax

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2032

Trials by Indication[1]

T-cell acute lymphoblastic leukemia1 trial

Neuroendocrine Tumors1 trial

Endometrial Cancer1 trial

References

Drug Info

Quick Facts

Related News